HC Wainwright Upgrades BioStem Technologies (OTCMKTS:BSEM) to Strong-Buy

BioStem Technologies (OTCMKTS:BSEM) was upgraded by equities research analysts at HC Wainwright to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

Separately, Zacks Research upgraded shares of BioStem Technologies to a “hold” rating in a research report on Wednesday, March 18th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, BioStem Technologies currently has a consensus rating of “Buy” and an average target price of $9.00.

BioStem Technologies Trading Down 4.3%

BSEM stock opened at $4.18 on Wednesday. The firm’s 50-day moving average price is $4.95 and its two-hundred day moving average price is $4.85. BioStem Technologies has a 12-month low of $3.09 and a 12-month high of $15.45. The stock has a market capitalization of $71.00 million, a price-to-earnings ratio of -9.86 and a beta of 0.09.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.